A new RRx-001 clinical trial is about to start (use the search box for my previous posts on it). Briefly: this is the drug which 1.) in preliminary data appears to sensitize multiple patients to previously failed irinotecan 2.) has very few side effects seen thus far. It's largest current trial is a randomized trial against Stivarga where RRx-001 is dosed sequentially: first RRx-001, then irinotecan. Just for the few people that don't know, irinotecan is the key component to FOLFIRI.
A new trial is about to start which does the next logical step - ask the question: if you dose RRx-001 simultaneously with irinotecan do you prevent/delay the emergence of resistance and gain a significant amount of time before progression?? Unlike the current Phase 2 trial for CRC, this trial is not being randomized so you're not being chanced with ending up with Stivarga...
The inclusion criteria are quite lenient. Brain mets allowed. You can either have had "or declined" standard of care chemo.
It is in two locations Northern California (Davis) and the east coast (NJ).
https://clinicaltrials.gov/ct2/show/NCT ... 097&rank=1